新工厂建成之后，多款新药都需要在丹麦、天津两地进行生产。可按照国家药监局的要求，生物制剂要 在同一个工厂内完成制造。鼓励生物医药创新发展，去年3月份，利用自贸区和综保区叠加的优势，市 商务局联合属地经开区、药监局、海关等六部门，成立诺和诺德服务专班，多次跟商务部、国家药监局 等部委进行沟通，争取分段生产试点。去年10月，国家药监局出台《生物制品分段生产试点工作方 案》，今年1月，本市也出台政策，支持企业争取生物制品在津分段生产试点。 总部在丹麦的诺和诺德落地经开区超过30年，目前，企业已经将22款创新药物和11款注射装置引入中 国，放在天津工厂生产，国内400多家供应商，有70％来自京津冀地区。看好中国大市场，以及供应链 优势，去年，企业在经开区投资40亿，扩建无菌制剂生产项目，目前，已经进入室内装修阶段，预计年 底之前完工。 党的二十届四中全会提出，"稳步扩大制度型开放"。市委十二届七次全会作出部署，要进一步全面深化 改革开放，充分激发各类经营主体活力。天津持续探索制度创新，推动外资企业增资扩产。两年里，全 球生物医药龙头企业诺和诺德在津增资近50亿元扩建的无菌制剂项目即将完工。 服务专班也邀请了国家药监局 ...

Group 1 - Baxter International Inc. announced the appointment of Andrew Hider as President and CEO, effective no later than September 3, 2025 [1] - Brent Shafer, who has served as Chairman and interim CEO since February 2025, will transition to the role of independent Chairman of the Board [1] Group 2 - Andrew Hider has 25 years of cross-industry experience and a global perspective, focusing on growth-oriented and people-centric leadership [2] - Hider served as CEO and Director of ATS, a leading automation solutions provider, where he significantly improved profit margins and nearly doubled adjusted revenue over five years with a compound annual growth rate (CAGR) in the low double digits [4][5] - Under Hider's leadership, ATS's stock price more than doubled since 2017, outperforming major indices [5] Group 3 - Baxter International, founded in 1931 and headquartered in Deerfield, Illinois, specializes in medical products for chronic and critical care, developing and selling products for complex conditions such as hemophilia and cancer [6] - Baxter's diverse business integrates medical devices, pharmaceuticals, and biotechnology, with a leading position in home kidney therapy and recombinant factor products for bleeding disorders [6] - The company employs approximately 38,000 members globally [6]